126 related articles for article (PubMed ID: 32139438)
1. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).
Rohr I; Alavi S; Richter R; Keller M; Chekerov R; Oskay-Özcelik G; Heinrich M; Taskiran C; Joly F; Berger R; du Bois A; Gornjec A; Vergote I; Achimas-Cadariu P; Lorusso D; Maenpaa J; Sehouli J
Int J Gynecol Cancer; 2020 Apr; 30(4):509-514. PubMed ID: 32139438
[TBL] [Abstract][Full Text] [Related]
2. [Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].
Lorcet M; Lortholary A; Kurtz JE; Berton-Rigaud D; Fabbro M; De La Motte Rouge T; Kaminsky-Forrett MC; Floquet A; Freyer G; Combe P; Dohollou N; Kalbacher E; Despax R; Largillier R; Hardy Bessard AC; Gane N; Sehouli J; Oskay-Oezcelik G; Licaj I; Ray-Coquard I; Joly Lobbedez F
Bull Cancer; 2018 May; 105(5):465-474. PubMed ID: 29544693
[TBL] [Abstract][Full Text] [Related]
3. Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.
Oskay-Özcelik G; Alavi S; Richter R; Keller M; Chekerov R; Cecere SC; Cormio G; Joly F; Kurtz JE; du Bois A; Maciejewski M; Jedryka M; Vergote I; Van Nieuwenhuysen E; Casado A; Mendiola C; Achimas-Cadariu P; Vlad C; Reimer D; Zeimet AG; Friedlander M; Sehouli J
Ann Oncol; 2018 Apr; 29(4):910-916. PubMed ID: 29415128
[TBL] [Abstract][Full Text] [Related]
4. Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
Dimitrova D; Naghavi B; Richter R; Nasser S; Chekerov R; Braicu EI; David M; Blohmer J; Inci G; Torsten U; Oskay-Özcelik G; Blau I; Fersis N; Holzgreve A; Keil E; Keller M; Keilholz U; Sehouli J
BMC Cancer; 2021 Sep; 21(1):1018. PubMed ID: 34511112
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
PEBC’s Ovarian Oncology Guidelines Group
Gynecol Oncol; 2017 Aug; 146(2):392-398. PubMed ID: 28601379
[TBL] [Abstract][Full Text] [Related]
6. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
[TBL] [Abstract][Full Text] [Related]
7. Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Havrilesky LJ; Lim S; Ehrisman JA; Lorenzo A; Alvarez Secord A; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2020 Mar; 156(3):561-567. PubMed ID: 31982178
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
Frey MK; Ellis AE; Koontz LM; Shyne S; Klingenberg B; Fields JC; Chern JY; Blank SV
Gynecol Oncol; 2017 Aug; 146(2):386-391. PubMed ID: 28602549
[TBL] [Abstract][Full Text] [Related]
9. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
Piccirillo MC; Scambia G; Bologna A; Signoriello S; Vergote I; Baumann K; Lorusso D; Murgia V; Sorio R; Ferrandina G; Sacco C; Cormio G; Breda E; Cinieri S; Natale D; Mangili G; Pisano C; Cecere SC; Di Napoli M; Salutari V; Raspagliesi F; Arenare L; Bergamini A; Bryce J; Daniele G; Gallo C; Pignata S; Perrone F
Ann Oncol; 2018 May; 29(5):1189-1194. PubMed ID: 29462248
[TBL] [Abstract][Full Text] [Related]
10. The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
Havrilesky LJ; Scott AL; Davidson BA; Secord AA; Yang JC; Johnson FR; Gonzalez JM; Reed SD
Gynecol Oncol; 2021 Aug; 162(2):440-446. PubMed ID: 34053748
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
12. Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO-ENGOT trial: EXPRESSION III.
Achimaş-Cadariu P; Iancu M; Kubelac P; Pop F; Braicu I; Vlad C; Oskay-Özcelik G; Sehouli J
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27507600
[TBL] [Abstract][Full Text] [Related]
13. Patient preferences in advanced or recurrent ovarian cancer.
Havrilesky LJ; Alvarez Secord A; Ehrisman JA; Berchuck A; Valea FA; Lee PS; Gaillard SL; Samsa GP; Cella D; Weinfurt KP; Abernethy AP; Reed SD
Cancer; 2014 Dec; 120(23):3651-9. PubMed ID: 25091693
[TBL] [Abstract][Full Text] [Related]
14. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
Wong CN; Wong CN; Liu FS
Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
[TBL] [Abstract][Full Text] [Related]
15. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
Patnaik A; Doyle C; Oza AM
Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
17. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in ovarian cancer patients receiving chemotherapy.
Lakusta CM; Atkinson MJ; Robinson JW; Nation J; Taenzer PA; Campo MG
Gynecol Oncol; 2001 Jun; 81(3):490-5. PubMed ID: 11371144
[TBL] [Abstract][Full Text] [Related]
19. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA
Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]